Evogene Ltd.
EVGN
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.6M
$0.44
▲ +9.70%
P/E
-1.07
Mkt Cap
$4.6M
52-Wk Range
$0.35–$1.50
52-Week Range
$0.35 - $1.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 63.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary Computational Predictive Biology (CPB) platform using AI and big data
- Strategic partnerships with global agricultural and pharmaceutical leaders (BASF, Corteva, Bayer)
- Diversified product pipeline across high-growth sectors (agriculture, biotech, medical cannabis)
- Established presence in innovation hubs with global operational reach
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Revenue decline expected
Increasing adoption of AI-driven product discovery in agriculture and pharmaceuticals
Value
Valuation data unavailable
Momentum
Stable
-3.0% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying EVGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 18, 2026
AUG 18, 2026
Reported EPS of -$0.13 vs -$0.27 consensus (+51.9% surprise). Revenue of $347.0K vs $325.0K expected (+6.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+51.9%
Revenue trend · last 8Q
—
—
-42%
+46%
-82%
-81%
+58%
-61%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$605.1K
$560.3K
$850.0K
$307.4K
$108.5K
$109.2K
$1.3M
$347.0K
Margins · last 8Q
Gross
-2.3%
Operating
—
Profit
-509.5%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How EVGN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related